We offer hope to those with retinal diseases by providing access to clinical trials that could potentially improve their condition and advance the treatment outcomes for future patients
Current Clinical Trials
Central Vein Retinal Occlusion (CRVO)
Wet Age-Related Macular Degeneration (wAMD)
Geographic Atrophy (GA)
Intermediate Age-Related Macular Degeneration (iAMD)
Diabetic Macular Edema (DME)
Geographic Atrophy Study
The Boehringer Ingelheim GA study is a Phase 1 clinical trial aimed at evaluating the complement inhibitor BI771716 for treating Geographic Atrophy. The study involves either one or two intravitreal (IVT) injections and includes a 3-month follow-up period. Ideal candidates are individuals aged 50 or above with a visual acuity between 20/800 and 20/40. Notably, the study is open to patients with large lesion sizes or a history of Syfovre/Izervay use. Participants will receive a $100 stipend per visit, and travel accommodations are also provided.
The i-SIGHT (i-Lumen) study is a Phase I clinical trial focusing on a novel treatment for Dry AMD. What sets this study apart is its non-invasive approach—no injections are required, as the treatment involves a microcurrent stimulation device. Ideal participants are individuals aged 50 or above with a visual acuity ranging from 20/40 to 20/200 and specific retinal conditions. The study will last for 12 months, with the first five visits being treatment visits from Monday through Friday. Participants will receive a $75 stipend per visit, and travel accommodations are provided.
Apellis Pharmaceuticals, Inc
This Phase 4 observational study, known as Apellis 411 GARLAND, focuses on evaluating the FDA-approved treatment Pegcetacoplan (Syfovre) for Non-subfoveal GA. The ideal candidates for this study are individuals aged 60 or above who have not previously received Syfovre treatment and have a visual acuity of 20/200 or better. A unique feature of this study is that both eyes can be enrolled if they meet the criteria. The study will span 3 years, with specific stipends and travel accommodations to be determined.
This clinical trial aims to evaluate the effectiveness and safety of foselutoclax in treating Diabetic Macular Edema (DME). Approximately 40 patients will be enrolled and will receive either foselutoclax or the standard treatment, aflibercept, in a randomized fashion. The study will last for about 24 weeks, with the primary objectives being to compare the efficacy and safety profiles of the two treatments.
CONQUER is a phase 1 clinical study to test the safety and efficacy of a new therapy called AM712 to treat Neovascular Age-related Macular Degeneration (nAMD). The study wants to see the drug’s efficacy in stabilizing the abnormal growth of blood vessels in the center region of the retina. Participants will enroll in the study for 16 weeks with a total of 11 visits.
This clinical trial aims to observe how intermediate age-related macular degeneration (iAMD) progresses to advanced stages of the disease. No treatment will be given in the study as the main goal of the study is to learn more about iAMD. Participants enrollment will last about 3 years with 12 follow up visits every 12 weeks.
To be eligible, participants must be between 50 and 95 years old with iAMD.
The OnwarD study tests a new medicine for adults with an advanced form of dry AMD called geographic atrophy (GA). The study drug is called danicopan, an oral tablet taken once or twice a day. Participants will be enrolled in the study for up to 2 years and 3 months. In the first year, participants will take either the medicine or a placebo but only the medicine in the second year.
To be eligible, participants must be 60 years or older and have dry AMD in at least one eye.
This study aims to compare the effectiveness of different approved drugs for preventing macular edema after cataract surgery. Participants are assigned to either receive steroid or anti-VEGF injections. After their cataract surgery, the patients will come to the clinic once a month for follow up visits for 3 months. The study is not experimental, so insurance will be billed for all examinations, treatments, and medications.
To be eligible for the study, participants must be at least 18 years of age with a diagnosis of Type 1 or 2 Diabetes.
This study is designed to evaluate a new drug’s safety and effectiveness for the treatment of diabetic macular edema (DME) in combination with ranibizumab. The drug is expected to inhibit molecules that contribute to inflammation and will be compared to ranibizumab, one of the standard treatments for DME. The study duration is up to 72 weeks with visits every month.
To be eligible for the study, participants must be at least 18 years of age or older, have been diagnosed with Type 1/2 Diabetes and DME associated with Diabetic Retinopathy.
This study is designed to evaluate a new drug’s safety and effectiveness for the treatment of diabetic macular edema (DME). The drug is expected to inhibit molecules that contribute to inflammation and will be compared to ranibizumab, one of the standard treatments for DME. The study duration is up to 72 weeks with visits every month.
To be eligible for the study, participants must be at least 18 years of age or older, have been diagnosed with Type 1/2 Diabetes and DME associated with Diabetic Retinopathy, and willing to allow Aqueous Humor collection
The purpose of this study is to investigate the effects (good or bad) of R07497372, the study drug, in participants with Diabetic Macular Edema (DME). In this study, you will get the study drug. Over 36 weeks, you will receive a total of 3 injections every 4 weeks throughout the study.
You may be eligible if at least 18 years of age or older, have been diagnosed with Type 1/2 Diabetes and DME associated with Diabetic Retinopathy.
This study offers a new gene-therapy drug that has potential to treat geographic atrophy secondary to age-related macular degeneration. Participants will be asked to attend 13 clinic visits over 18 months for health and eye exams.
Potentially eligible if 60 years or older and diagnosed with geographic atrophy.